Table 1.
Demographics and characteristics of the vaccinated cohorts.
|
BNT162b2 (15 μg) |
BNT162b2 (30 μg)ɣ |
mRNA-1273 (50 μg) |
mRNA-1273 (100 μg)ɣ |
|
|---|---|---|---|---|
| Total number (n) | 59 | 54 | 51 | 58 |
| Mean age ± SD (years) | 39.1 ± 10.0 | 41.6 ± 10.1 | 38.7 ± 11.1 | 37.0 ± 10.5 |
| Sex | ||||
| Male (%) | 28 (47.5 %) | 32 (59.3 %) | 22 (43.1 %) | 28 (47.8 %) |
| Female (%) | 31 (52.5 %) | 22 (40.7 %) | 29 (56.8 %) | 30 (52.2 %) |
| Underlying disease (%) | ||||
| Allergy | 4 (6.8 %) | 4 (7.4 %) | 5 (9.8 %) | 4 (6.9 %) |
| Diabetes Mellitus | 3 (5.1 %) | 2 (3.7 %) | – | 2 (3.4 %) |
| Dyslipidemia | 3 (5.1 %) | 4 (7.4 %) | – | 1 (1.7 %) |
| Hypertension | 5 (8.5 %) | 6 (11.1 %) | 3 (5.8 %) | 4 (6.9 %) |
| Thyroid | 1 (1.7 %) | 2 (3.7 %) | 1 (1.9 %) | 1 (1.7 %) |
| Others | 2 (3.4 %) | 3 (5.6 %) | 3 (5.8 %) | 2 (3.4 %) |
| Follow-up | ||||
| Second visit (two weeks) | ||||
| Mean (range) days | 18.5 (14–21) | 14.3 (13–21) | 15.5 (14–21) | 16 (14–20) |
| Lost to follow-up (n) | 3 | 1 | 1 | 0 |
| Third visit (four weeks) | ||||
| Mean (range) days | 28.6 (27–30) | 28.3 (27–35) | 28.1 (28–29) | 27.9 (22–35) |
| Lost to follow-up (n) | 3 | 0 | 5 | 2 |
Inactive disease—no medication involving immunosuppressant. ɣ Previous enrolled participants of standard dose vaccination [7].